logo.PNG
Ark Biopharmaceutical Announces NMPA Acceptance and Priority Review of New Drug Application for Ziresovir for Treatment of RSV Infection
December 08, 2022 20:00 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical), a biopharma company dedicated to the discovery and development of drugs for...
logo.PNG
愛科百發宣佈呼吸道合胞病毒新藥愛司韋®的上市許可申請獲國家藥品監督管理局正式受理並納入優先審評審批程式
December 08, 2022 20:00 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
中國上海, Dec. 09, 2022 (GLOBE NEWSWIRE) -- 上海愛科百發生物醫藥技術股份有限公司(以下簡稱“ 愛科百發”),一家致力於兒科及呼吸疾病領域創新藥研發的生物製藥企業,今日宣佈中國國家藥品監督管理局正式受理治療呼吸道合胞病毒(RSV)感染新藥愛司韋®(通用名:齊瑞索韋/ziresovir)的上市許可申請(NDA),並且納入“優先審評審批”程式。 ...
logo.PNG
爱科百发宣布呼吸道合胞病毒新药爱司韦®的上市许可申请获国家药品监督管理局正式受理并纳入优先审评审批程序
December 08, 2022 20:00 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Dec. 09, 2022 (GLOBE NEWSWIRE) -- 上海爱科百发生物医药技术股份有限公司(以下简称“ 爱科百发”),一家致力于儿科及呼吸疾病领域创新药研发的生物制药企业,今日宣布中国国家药品监督管理局正式受理治疗呼吸道合胞病毒(RSV)感染新药爱司韦®(通用名:齐瑞索韦/ziresovir)的上市许可申请(NDA),并且纳入“优先审评审批”程序。 ...
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
October 10, 2022 12:04 ET | AB Science
PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHORIZATIONS TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10th 2022, 6pm...
AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
October 10, 2022 12:04 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A REÇU LES PREMIÈRES AUTORISATIONS RÈGLEMENTAIRES POUR INITIER UNE ÉTUDE CLINIQUE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA MALADIE...
logo 600X600.png
Global Extracorporeal Membrane Oxygenation System Market to Surpass US$ 476.8 Million by 2030, Says Coherent Market Insights (CMI)
July 12, 2022 09:10 ET | CMI
Seattle, July 12, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global extracorporeal membrane oxygenation system market is estimated to be valued at US$ 316.5 million in 2022...
Eventa LLC Welcomes Michelle Harrison as Director of Business
June 17, 2022 09:00 ET | Eventa LLC
LIVINGSTON, Tenn., June 17, 2022 (GLOBE NEWSWIRE) -- Eventa LLC, leading experts in post-acute respiratory care, complex airway care, long-term ventilation and liberation, welcomes Michelle Harrison...
new_logo.png
North America Precision Medicine Market size to surpass $50bn by 2027, says Graphical Research
May 02, 2022 07:07 ET | Graphical Research
Pune, India, May 02, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America precision medicine market is forecast to register its name in the...
logo.PNG
ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection
April 07, 2022 03:50 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 3 AirFLO study with ziresovir met primary and key secondary endpoints of significant reduction of sign-and-symptom score (p=0.002) and viral load (p=0.006) respectively, compared with...
logo.PNG
愛科百發宣佈愛司韋™在治療呼吸道合胞病毒(RSV)感染的住院嬰幼兒中的臨床三期試驗達到主要終點
April 07, 2022 03:50 ET | Shanghai Ark Biopharmaceutical Co., Ltd.
在臨床三期AirFLO試驗中,愛司韋™與安慰劑相比顯著降低症狀評分(p=0.002)及病毒載量(p=0.006),達到試驗主要終點和關鍵次要終點 RSV感染是五歲以下兒童因病毒感染而住院及死亡的首要因素愛司韋™是全球首個成功在兒童患者人群中完成關鍵性三期臨床研究的RSV抗病毒藥物愛司韋™計畫於2022年年中向中國監管機構提交新藥上市申請 上海, April 07, 2022 ...